DOCSLIB.ORG
  • Sign Up
  • Log In
  • Upload
  • Sign Up
  • Log In
  • Upload
  • Home
  • »  Tags
  • »  Semustine

Semustine

  • Trade-To-Generic Names

    Trade-To-Generic Names

  • Phenotype Microarrays Panels PM-M1 to PM-M14

    Phenotype Microarrays Panels PM-M1 to PM-M14

  • NINDS Custom Collection II

    NINDS Custom Collection II

  • A Comparison Between Triplet and Doublet Chemotherapy in Improving

    A Comparison Between Triplet and Doublet Chemotherapy in Improving

  • Covalently-Linked Complexes and Methods for Enhanced Cytotoxicity and Imaging

    Covalently-Linked Complexes and Methods for Enhanced Cytotoxicity and Imaging

  • Appendix C Medication Tables

    Appendix C Medication Tables

  • (12) United States Patent (10) Patent No.: US 9,283,215 B2 Zeldis (45) Date of Patent: *Mar

    (12) United States Patent (10) Patent No.: US 9,283,215 B2 Zeldis (45) Date of Patent: *Mar

  • Antigen Binding Protein and Its Use As Addressing Product for the Treatment of Cancer

    Antigen Binding Protein and Its Use As Addressing Product for the Treatment of Cancer

  • Combined Modality Approaches in the Management of Adult Glioblastoma

    Combined Modality Approaches in the Management of Adult Glioblastoma

  • (12) Patent Application Publication (10) Pub. No.: US 2015/0150995 A1 Taft, III Et Al

    (12) Patent Application Publication (10) Pub. No.: US 2015/0150995 A1 Taft, III Et Al

  • Stembook 2018.Pdf

    Stembook 2018.Pdf

  • Download This Topic [PDF]

    Download This Topic [PDF]

  • Shweta Agarwal Dr. Ranjana Mehrotra

    Shweta Agarwal Dr. Ranjana Mehrotra

  • DNA Damage, Repair and Cell Death Signaling

    DNA Damage, Repair and Cell Death Signaling

  • Safe Handling of Hazardous Chemotherapy Drugs in Limited-Resource Settings

    Safe Handling of Hazardous Chemotherapy Drugs in Limited-Resource Settings

  • Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes

    Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes

  • United States Patent (19) 11 Patent Number: 5,728,680 Morozov Et Al

    United States Patent (19) 11 Patent Number: 5,728,680 Morozov Et Al

  • Supplement 1A. Antineoplastic Medications Samples of the Intervention Group

    Supplement 1A. Antineoplastic Medications Samples of the Intervention Group

Top View
  • Marrakesh Agreement Establishing the World Trade Organization
  • Minimal Residual Disease Prior to Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia: a Meta-Analysis
  • Pharmaceutical Compositions and Dosage Forms of Thalidomide
  • Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs
  • United States Patent $835 a 88: As: Inhibitor 1-((R)-3-(4-Amino-3-(4
  • LEADING ARTICLE Causality of Myelodysplasia and Acute Myeloid
  • Table 1. Database for Drugs Analyzed in This Study. Mechanism Mean Average # Mechanism Mean Average # of Action* Drug† NSC No
  • Modified Bucy Is an Alternative Conditioning Regimen for Lymphoma Patients Undergoing Autologous Stem Cell Transplantation
  • Adjuvant Therapy in Resectable Gastric Cancer
  • Efficacy of Allogeneic and Autologous Hematopoietic SCT in Patients With
  • Secondary Cancers: Who Is at Risk?
  • FDA-Approved Drug Screening for Compounds That Facilitate Hematopoietic Stem and Progenitor Cells (Hspcs) Expansion in Zebrafish
  • Cytostatics in the Aquatic Environment: Analysis, Occurrence, and Possibilities for Removal
  • Systemic Enzyme Therapy in Oncology Effect and Mode of Action
  • Molecular Blueprints for Antitumor Drugs
  • Review of Medicines for the Treatment of Common Tumours in Children
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
  • Templated Nanoconjugates Joshua Cutler, Weston Daniel, David Giljohann, Chad Mirkin, Ke Zhang, Dan Zheng Issue Date


© 2024 Docslib.org    Feedback